Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine
P. L. Zinzani, M. Magagnoli, M. Bendandi, M. Tani, V. Stefoni, C. Cellini, S. Poggi, M. Piccioli, S. Pileri, S. Tura
Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.
2-CdA
9-year follow-up
Re-treated patients
Dive into the research topics of 'Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine'. Together they form a unique fingerprint.
Cladribine Medicine & Life Sciences 100%
Hairy Cell Leukemia Medicine & Life Sciences 93%
Survival Medicine & Life Sciences 10%
Pentostatin Medicine & Life Sciences 9%
Interferons Medicine & Life Sciences 5%
Therapeutics Medicine & Life Sciences 1%
Zinzani, P. L., Magagnoli, M., Bendandi, M., Tani, M., Stefoni, V., Cellini, C., Poggi, S., Piccioli, M., Pileri, S., & Tura, S. (2000). Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica, 85(9), 922-925.
Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. / Zinzani, P. L.; Magagnoli, M.; Bendandi, M. et al.
In: Haematologica, Vol. 85, No. 9, 2000, p. 922-925.
Zinzani, PL, Magagnoli, M, Bendandi, M, Tani, M, Stefoni, V, Cellini, C, Poggi, S, Piccioli, M, Pileri, S & Tura, S 2000, 'Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine', Haematologica, vol. 85, no. 9, pp. 922-925.
Zinzani PL, Magagnoli M, Bendandi M, Tani M, Stefoni V, Cellini C et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica. 2000;85(9):922-925.
Zinzani, P. L. ; Magagnoli, M. ; Bendandi, M. et al. / Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. In: Haematologica. 2000 ; Vol. 85, No. 9. pp. 922-925.
@article{245eae7014c74748aeaf297a720270f3,
title = "Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine",
abstract = "Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.",
keywords = "2-CdA, 9-year follow-up, HCL, Re-treated patients",
author = "Zinzani, {P. L.} and M. Magagnoli and M. Bendandi and M. Tani and V. Stefoni and C. Cellini and S. Poggi and M. Piccioli and S. Pileri and S. Tura",
journal = "Haematologica",
publisher = "NLM (Medline)",
T1 - Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine
AU - Zinzani, P. L.
AU - Magagnoli, M.
AU - Bendandi, M.
AU - Tani, M.
AU - Stefoni, V.
AU - Cellini, C.
AU - Poggi, S.
AU - Piccioli, M.
AU - Pileri, S.
AU - Tura, S.
N2 - Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.
AB - Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.
KW - 2-CdA
KW - 9-year follow-up
KW - HCL
KW - Re-treated patients
JO - Haematologica
JF - Haematologica